These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38752572)
1. Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Schettini F; Blondeaux E; Molinelli C; Bas R; Kim HJ; Di Meglio A; Bernstein Molho R; Linn SC; Pogoda K; Carrasco E; Punie K; Agostinetto E; Lopetegui-Lia N; Phillips KA; Toss A; Rousset-Jablonski C; Acheritogaray M; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Puglisi F; Vasconcelos de Matos L; Mariño M; Teixeira L; Graffeo R; Rognone A; Chirco A; Antone N; Abdou Y; Marhold M; Božović-Spasojević I; Cortés Salgado A; Carmisciano L; Bruzzone M; Curigliano G; Prat A; Lambertini M Cancer; 2024 Aug; 130(16):2746-2762. PubMed ID: 38752572 [TBL] [Abstract][Full Text] [Related]
2. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. Arecco L; Bruzzone M; Bas R; Kim HJ; Di Meglio A; Bernstein-Molho R; Hilbers FS; Pogoda K; Carrasco E; Punie K; Bajpai J; Agostinetto E; Lopetegui-Lia N; Partridge AH; Phillips KA; Toss A; Rousset-Jablonski C; Curigliano G; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Couch FJ; Dieci MV; Matikas A; Rozenblit M; Aguilar-Y Méndez D; De Marchis L; Puglisi F; Fabi A; Graff SL; Witzel I; Rodriguez Hernandez A; Fontana A; Pesce R; Duchnowska R; Pais HL; Sini V; Sokolović E; de Azambuja E; Ceppi M; Blondeaux E; Lambertini M Ann Oncol; 2024 Sep; 35(9):792-804. PubMed ID: 38908482 [TBL] [Abstract][Full Text] [Related]
3. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Akkoc Mustafayev FN; Shukla MA; Lanier A; Milton DR; Gutierrez AM; Gruschkus SK; Lewis JE; Murthy RK; Arun BK Cancer; 2024 May; 130(9):1600-1608. PubMed ID: 38100492 [TBL] [Abstract][Full Text] [Related]
4. Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants. Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009 [TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364 [TBL] [Abstract][Full Text] [Related]
9. Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis. Ben-Zion Berliner M; Yust-Katz S; Lavie I; Goldberg Y; Kedar I; Yerushalmi R BMC Cancer; 2024 Feb; 24(1):219. PubMed ID: 38365640 [TBL] [Abstract][Full Text] [Related]
10. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients. Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965 [TBL] [Abstract][Full Text] [Related]
12. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407 [TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037 [TBL] [Abstract][Full Text] [Related]
14. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428 [TBL] [Abstract][Full Text] [Related]
15. Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. Evans DG; Woodward ER; Howell SJ; Verhoef S; Howell A; Lalloo F Fam Cancer; 2017 Apr; 16(2):173-179. PubMed ID: 27796713 [TBL] [Abstract][Full Text] [Related]
16. What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy? Forester E; Belsare A; Kim DW; Whitaker K; Obeid E; Goldstein LJ; Bleicher RJ; Daly MB; Williams AD J Surg Res; 2024 Jul; 299():217-223. PubMed ID: 38776577 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564 [TBL] [Abstract][Full Text] [Related]
18. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Kuchenbaecker KB; Neuhausen SL; Robson M; Barrowdale D; McGuffog L; Mulligan AM; Andrulis IL; Spurdle AB; Schmidt MK; Schmutzler RK; Engel C; Wappenschmidt B; Nevanlinna H; Thomassen M; Southey M; Radice P; Ramus SJ; Domchek SM; Nathanson KL; Lee A; Healey S; Nussbaum RL; Rebbeck TR; Arun BK; James P; Karlan BY; Lester J; Cass I; ; Terry MB; Daly MB; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; v O Hansen T; Ejlertsen B; Gerdes AM; Nielsen FC; Dennis J; Cunningham J; Hart S; Slager S; Osorio A; Benitez J; Duran M; Weitzel JN; Tafur I; Hander M; Peterlongo P; Manoukian S; Peissel B; Roversi G; Scuvera G; Bonanni B; Mariani P; Volorio S; Dolcetti R; Varesco L; Papi L; Tibiletti MG; Giannini G; Fostira F; Konstantopoulou I; Garber J; Hamann U; Donaldson A; Brewer C; Foo C; Evans DG; Frost D; Eccles D; ; Douglas F; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Eeles R; Davidson R; Hodgson S; Ellis S; Godwin AK; Rhiem K; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Steinemann D; Bogdanova-Markov N; Kast K; Varon-Mateeva R; Wang-Gohrke S; Gehrig A; Markiefka B; Buecher B; Lefol C; Stoppa-Lyonnet D; Rouleau E; Prieur F; Damiola F; ; Barjhoux L; Faivre L; Longy M; Sevenet N; Sinilnikova OM; Mazoyer S; Bonadona V; Caux-Moncoutier V; Isaacs C; Van Maerken T; Claes K; Piedmonte M; Andrews L; Hays J; Rodriguez GC; Caldes T; de la Hoya M; Khan S; Hogervorst FB; Aalfs CM; de Lange JL; Meijers-Heijboer HE; van der Hout AH; Wijnen JT; van Roozendaal KE; Mensenkamp AR; van den Ouweland AM; van Deurzen CH; van der Luijt RB; ; Olah E; Diez O; Lazaro C; Blanco I; Teulé A; Menendez M; Jakubowska A; Lubinski J; Cybulski C; Gronwald J; Jaworska-Bieniek K; Durda K; Arason A; Maugard C; Soucy P; Montagna M; Agata S; Teixeira MR; ; Olswold C; Lindor N; Pankratz VS; Hallberg E; Wang X; Szabo CI; Vijai J; Jacobs L; Corines M; Lincoln A; Berger A; Fink-Retter A; Singer CF; Rappaport C; Kaulich DG; Pfeiler G; Tea MK; Phelan CM; Mai PL; Greene MH; Rennert G; Imyanitov EN; Glendon G; Toland AE; Bojesen A; Pedersen IS; Jensen UB; Caligo MA; Friedman E; Berger R; Laitman Y; Rantala J; Arver B; Loman N; Borg A; Ehrencrona H; Olopade OI; Simard J; Easton DF; Chenevix-Trench G; Offit K; Couch FJ; Antoniou AC; Breast Cancer Res; 2014 Dec; 16(6):3416. PubMed ID: 25919761 [TBL] [Abstract][Full Text] [Related]
19. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China. Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898 [TBL] [Abstract][Full Text] [Related]
20. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]